OUR SCIENCE
Targeted diseases
​​
At Eder Therapeutics, we specialize in rare diseases. With our partnership with ECOGENE-21, we have a unique ability to increase the understanding of rare diseases, outcomes, and patient journeys, enabling maximal benefit for patients, their families, and all stakeholders. Our focus also extends to diseases with unique dietary needs that are central to the intervention plan but often insufficient or highly restrictive in controlling the disease and managing complications.
​
That’s where Eder Therapeutics comes in. Our integrated offering is ideal for a wide array of rare diseases.
OUR PORTFOLIO
Providing optimal pharmacological solutions for patients living with rare diseases
For all targeted diseases, our goal is to complement the pharmacological treatment with an adapted integrated care approach, providing an optimal solution that will highly impact the quality of life of patients living with rare diseases.
Our first pipeline asset is a potentially improved AAV gene replacement therapy for LPL deficiency, a rare and severe lipid disease.
LPL gene therapy (AAV-based) for LPL deficiency
By adding episomal copies of functional LPL genes into muscle cells lacking active LPL, metabolic function may be improved or restored.